How to buy Sutro Biopharma stock | $22.04

Sutro Biopharma, Inc is a biotechnology business based in the US. Sutro Biopharma shares (STRO) are listed on the NASDAQ and all prices are listed in US Dollars. Sutro Biopharma employs 182 staff and has a trailing 12-month revenue of around USD$45.7 million.

How to buy shares in Sutro Biopharma

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Sutro Biopharma. Find the stock by name or ticker symbol: STRO. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Sutro Biopharma reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$22.04, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Sutro Biopharma, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Sutro Biopharma. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Sutro Biopharma share price

Use our graph to track the performance of STRO stocks over time.

Sutro Biopharma shares at a glance

• Key figures

Information last updated 2020-12-02.

Latest market close	USD$22.04
52-week range	USD$6 - USD$19.18
50-day moving average	USD$14.7789
200-day moving average	USD$10.8841
Wall St. target price	USD$21
PE ratio	38.0952
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$0.441

Buy Sutro Biopharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Sutro Biopharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Sutro Biopharma, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Sutro Biopharma price performance over time

Historical closes compared with the close of $22.04 from 2020-12-09

1 week (2021-01-13)	N/A
1 month (2020-12-24)	-0.18%
3 months (2020-10-20)	N/A
6 months (2020-07-20)	N/A

1 year (2020-01-20)	N/A
2 years (2019-01-20)	N/A
3 years (2018-01-20)	N/A
5 years (2016-01-20)	N/A

Is Sutro Biopharma under- or over-valued?

Valuing Sutro Biopharma stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Sutro Biopharma's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Sutro Biopharma's P/E ratio

Sutro Biopharma's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 38x. In other words, Sutro Biopharma shares trade at around 38x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Sutro Biopharma financials

Revenue TTM	USD$45.7 million
Gross profit TTM	USD$-22,876,000
Return on assets TTM	-15.96%
Return on equity TTM	7.13%
Profit margin	27.6%
Book value	$6.409
Market capitalisation	USD$648.6 million

TTM: trailing 12 months

Shorting Sutro Biopharma shares

There are currently 2.6 million Sutro Biopharma shares held short by investors – that's known as Sutro Biopharma's "short interest". This figure is 1.7% down from 2.6 million last month.

There are a few different ways that this level of interest in shorting Sutro Biopharma shares can be evaluated.

Sutro Biopharma's "short interest ratio" (SIR)

Sutro Biopharma's "short interest ratio" (SIR) is the quantity of Sutro Biopharma shares currently shorted divided by the average quantity of Sutro Biopharma shares traded daily (recently around 236293.27272727). Sutro Biopharma's SIR currently stands at 11. In other words for every 100,000 Sutro Biopharma shares traded daily on the market, roughly 11000 shares are currently held short.

However Sutro Biopharma's short interest can also be evaluated against the total number of Sutro Biopharma shares, or, against the total number of tradable Sutro Biopharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Sutro Biopharma's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Sutro Biopharma shares in existence, roughly 70 shares are currently held short) or 0.0771% of the tradable shares (for every 100,000 tradable Sutro Biopharma shares, roughly 77 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Sutro Biopharma.

Find out more about how you can short Sutro Biopharma stock.

Sutro Biopharma share dividends

We're not expecting Sutro Biopharma to pay a dividend over the next 12 months.

Sutro Biopharma share price volatility

Over the last 12 months, Sutro Biopharma's shares have ranged in value from as little as $6 up to $19.18. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sutro Biopharma's is 0.4535. This would suggest that Sutro Biopharma's shares are less volatile than average (for this exchange).

Sutro Biopharma overview

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers. It has collaboration and license agreement with Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused primarily on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

Frequently asked questions

• What percentage of Sutro Biopharma is owned by insiders or institutions?

  Currently 12.691% of Sutro Biopharma shares are held by insiders and 98.742% by institutions.

• How many people work for Sutro Biopharma?

  Latest data suggests 182 work at Sutro Biopharma.

• When does the fiscal year end for Sutro Biopharma?

  Sutro Biopharma's fiscal year ends in December.

• Where is Sutro Biopharma based?

  Sutro Biopharma's address is: 310 Utah Avenue, South San Francisco, CA, United States, 94080

• What is Sutro Biopharma's ISIN number?

  Sutro Biopharma's international securities identification number is: US8693671021

• What is Sutro Biopharma's CUSIP number?

  Sutro Biopharma's Committee on Uniform Securities Identification Procedures number is: 869367102